• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: December 2022

Editor's Choice

Microbiome Drug Development: 2022 in Review

December 30, 2022 Luis Gosálbez

Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three […]

Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

December 22, 2022 Microbiome Times
Finance

Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics

December 22, 2022 Microbiome Times

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to […]

Pharma & Human Health

Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy

December 21, 2022 Microbiome Times

Cryo-electron microscopy by University of Alabama at Birmingham researchers has exposed the structure of a bacterial virus with unprecedented detail. This is the first structure of a virus able to infect Staphylococcus epidermidis, and high-resolution […]

Finance

Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment

December 16, 2022 Microbiome Times

Beiersdorf AG announced today that it has acquired a majority stake in S-Biomedic NV, Belgium, a life-science company and frontrunner in the field of skin microbiome research. Beiersdorf recognized the potential of the skin microbiome […]

Finance

A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation

December 13, 2022 Microbiome Times

On December 12th, Novozymes and Chr. Hansen, two of the world’s leading biosolutions corporations, entered into an agreement to merge into a novel company. Prompted by global megatrends, including climate considerations, food system security, and […]

Editor's Choice

FDA Approves First Fecal Microbiota Product

December 1, 2022 Microbiome Times

Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
  • Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
    March 5, 2025
sign up

Sign up to the Microbiome Times newsletter